Profil
Michael Wittekind worked as an Executive Director-Research at Amgen, Inc. from 2003 to 2007, an Associate Director at Bristol-Myers Squibb Pharmaceutical Research Institute, and a Chief Scientific Officer & Senior VP-Research at ContraFect Corp.
from 2014 to 2016.
He also worked as a Director-Process Development at Phylos, Inc. Dr. Wittekind holds a doctorate degree from the University of Wisconsin and a graduate degree from the University of Washington.
Ehemalige bekannte Positionen von Michael Wittekind
| Unternehmen | Position | Ende |
|---|---|---|
| CONTRAFECT CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2016 |
| AMGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2007 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | - |
Phylos, Inc.
Phylos, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical research and manufacturing services | Corporate Officer/Principal | - |
Ausbildung von Michael Wittekind
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Phylos, Inc.
Phylos, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical research and manufacturing services | Commercial Services |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
ContraFect Corp.
ContraFect Corp. BiotechnologyHealth Technology Engages in discovery and development of direct lytic agents for life-threatening & drug-resistant infectious diseases | Health Technology |
















